Phase 4 Crohn's Disease and Colitis Trial, Not Yet Recruiting NCT07564505 Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Condition: Crohn's Disease and Colitis
Back to Crohns Disease And Colitis

Phase 4 Crohn's Disease and Colitis Trial, Not Yet Recruiting

NCT07564505
Not Yet Recruiting Phase 4

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • The child or teenager must be between 6 and 17 years old (any gender).
  • They must have been diagnosed with moderate to severe active Crohn's disease in children, based on specific medical guidelines from 2019.
  • Their doctor must have already decided, after carefully weighing the risks and benefits, that Adalimumab injection (a specific medication) is the right treatment for them.
  • Both the patient and their parent or guardian must agree to take part and sign a consent form that meets local legal requirements.

Who may not be able to join:

  • If the treating doctor believes, based on the medication's guidelines, that Adalimumab injection is not appropriate for the child, they cannot join.
  • Children who have received any live vaccines (a type of vaccine that uses a weakened live virus) in the 3 months before starting the medication, or who plan to receive any live vaccines during the study, cannot join.
  • Children who are already taking part in another clinical trial cannot join.
  • Children who the trial doctor feels are not suitable for any other reason cannot join (confirm with trial site).

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 26 July 2026
Phase 4 trials study a drug that has already been approved, monitoring long-term safety and effectiveness in real-world use.

Contact this trial

Phone: 18902268612

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Not Yet Recruiting
Phase
Phase 4
Sponsor
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Registry
ClinicalTrials.gov
Start date
1 May 2026
Est. completion
1 March 2029

Primary endpoints

The incidence of adverse events (AE), adverse drug reactions (ADR), adverse events of special interest (AESI) and serious ADR at 12, 26 and 52 weeks after treatment

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 26 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov